The FDA has approved three additional dosage strengths of Opana ER (oxymorphone HCl, from Endo Pharmaceuticals) extended-release tablets. The 7.5mg, 15mg, and 30mg dosage strengths will be available in addition to the 5mg, 10mg, 20mg, and 40mg dosage strengths already on the market. Opana ER is indicated for the relief of moderate-to-severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. The additional strengths are expected to be available on April 1, 2008.
For more information call (800) 462-ENDO or visit www.opana.com.